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Abstract. This survey paper describes the necessity of the development of new medications 
influencing the body redox-potential. It supports the most pressing branch of pharmacology, 
which coincides with logically relevant attempts to shift paradigm of pharmacology from 
molecular to electronic, quantum-wave. This article covers and logically assorts research results 
of recent years and opinions of wide range of scientists from various countries. The authors also 
give their own assessment of the possibility to influence body redox potential. It is reported that 
some biophysical achievements regarded undoubtedly put a new spin in pharmacology of the 
biophysical level. These research results devoted to the role of redox-potential in regulation of 
biological systems are considered to open up new opportunities for pharmacotherapy of 
pathological conditions by developing medications of the new generation – redox-potential 
regulators - aimed at the induction of the body protective resources. The paper further reports that 
elaborate study of redox-potential in providing biological systems regulation has resulted in the 
detailed investigation of Mexidol benefits. Special attention is paid to the general principle of 
action of endogenous redox regulators: metabolic, energetic and informational. The article also 
highlights key issues of the regulation of oxidation-reduction processes in the body and, 
consequently, the role of reactive oxygen species in physiology and pathology. The paper 
reasonably concludes with the statement on the necessity to turn pharmacologists’ attention not 
only to improving the existing anti-oxidant preparations, but to developing the redox system 
regulators, which appear to be medications of the new generation for pathogenic therapy. 
Key words: reactive oxygen species, oxygen, reduction-oxidation reactions, redox potential, 
pharmacotherapy. 
 
Introduction. Use of oxygen to receive energy 
needed for the life-sustaining activity by substrate 
oxidation in biological objects is considered to be one 
of the mainstreams of the living systems evolution 
[1]. Functioning of the human body as the most 
highly organized life-form depends on oxygen 
supply; its deficiency causes multiple pathological 
conditions. Decrease of energy resources under 
hypoxia results in multisystemic and multiorganic 
functional-metabolic changes and, subsequently, 
death of the whole body.    
Oxygen is the leading factor of the biological 
rhythms control: circadian, seasonal, reproductive, as 
well as homeostasis, proliferation, differentiation, 
apoptosis, carcinogenesis, aging, necrosis and some 
other cellular processes [2-5], and their exact 
mechanisms can be understood only in the plant cell 
[6]. 
Aerobic organisms have oxidative potential, 
which increases with the increase of tissue blood 
supply or activation of free-radical particles. Oxygen 
deficiency, on the contrary, leads to reductive change 
of potential. Shift of the balance between prooxidants
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 and anti-oxidants induces oxidative stress 
characterized by specific changes of the cellular 
processes: membrane structure is violated due to lipid 
perioxidation, proteins are oxidated, DNA is 
damaged, cellular redox potential changes. 
There have been recorded instances of more than 
200 nosological forms accompanied by oxidative 
stress: cardio-vascular [7-14], oncological [15], 
infectious diseases [16, 17], pathologies of the 
respiratory [18], reproductive [19-21], urinary [22, 
23], nervous system, pyoinflammatory processes 
[24], arthritis of various types, diabetes mellitus, 
cataract and others [25].  
Mitochondrial respiratory chain, microsome 
electron-transport chain, arachidonic acid 
metabolism, hypoxanthine-xanthine oxidase 
reactions, biosynthesis and catecolamine oxidation 
are reported to be sources of reactive oxygen species 
(ROS) [26]. Mitochondrias are stated to be the main 
sources of radicals in a cell [27], therefore these 
organelles need to be constantly protected from 
damages induced by oxidative stress. Mitochondrial 
DNA appears to be the most vulnerable target for 
ROS. There exist a lot of evidences that its oxidative 
violation and increasing de-energization of oxygen-
dependant cells play the key role in the whole range 
of “mitochondrial diseases” [28, 29], 
neurodegenerative pathologies [30, 31], as well as 
body aging [32]. The final stage of this process is 
necrosis, due to which a cell as a living system stops 
existing, since transformation systems of substance 
and energy flows, permeability of cellular and sub-
cellular membranes are violated, ion gradients 
disappear [1]. Currently, the role of mitochondrias in 
regulation of proliferation and differentiation 
processes, apoptosis and cancerous growth is actively 
investigated. Change of ROS generation rate under 
influence of mitochondrias may be considered as one 
of the mechanisms that switch functional activity of a 
cell [33]. 
ROS comprises a lot of transitional products of 
oxygen metabolism producing in the body; they, in 
turn, having high reactive capacity can lead to 
violation of practically all structural components of 
the biological system [2, 33-36]. Increased ROS 
levels result in initiation of free-radical oxidation – 
the process of immediate oxygen transfer on substrate 
with formation of peroxides, ketones, aldehydes 
inducing reactions of peroxide oxidation. This 
ancient natural destructive mechanism that has a hold 
over all the organic compounds is necessary for the 
following renovation of cells and tissues, their 
adaptation for the changing environment, body 
protection against infections, participation in 
formation of biologically active compounds. This 
implies the fact that presence of free radicals in a 
body has specific, physiologically important 
significance [37]. 
On the other hand, it is beyond argument that 
functional properties of some enzymes, 
carbohydrates, proteins, DNA and RNA are changed 
under the influence of free-radicals so that a cell loses 
its regulatory functions [2]. Concurrently there may 
appear abnormal proteins; secondary destructive 
processes may be stimulated apart from direct 
damaging action.  
 
Discussion. The leading role in pathogenesis of 
radiation damage, inflammatory processes of various 
localization and origin, development of hyper- and 
hypoxic conditions, post-ischemic, reperfusion and 
hyperoxic disorders, wound processes, stress, acute 
and chronic hepatic diseases, myocardial infarction, 
strokes, atherosclerosis, carcinogenesis, aging and so 
on belongs to lipid peroxidation. Influence of free-
radicals on structure and functions of biological 
membranes is one of the most important pathogenic 
mechanisms in hypoxia.  
There is a multilevel physiological system of 
protection against oxidation agents in a body – the 
antioxidant system supporting oxidative-antioxidative 
balance in all organs and systems [38, 39]. The 
antioxidant system includes the whole complex of 
enzymes: superoxide dismutase (SOD), catalase, 
glutathione-dependant peroxidases, transferases etc., 
as well as a range of cellular metabolites: lipoic, 
ascorbic, uric acids, tocopherols, carotenoids, 
flavonoids, polyphenols, carnosine, bilirubin, 
coenzyme Q10 and other compounds aimed at 
maintaining the normal reactions of the body in 
various pathological conditions, including hypoxia 
[2, 32, 40-50]. Malfunctioning of these systems is 
stated to be one of the most significant factors in 
violation of prooxidant-antioxidant balance and 
oxidative stress development [51, 52]. Some research 
studies have demonstrated that ROS formation and 
multicomponent anti-oxidative protection constitute 
the unified system being in the dynamic balance and 
having capacity for self-regulation [35]. Due to the 
associated functioning of the ROS generation and 
anti-oxidative protection systems oxidation-reduction 
balance is established in a cell, in other words redox 
status. Redox potential formation reflecting balance 
status of the pro- and antioxidant body systems [53] 
is greatly influenced by protein components of blood 
plasma, catalase enzyme activity  and, possibly, 
alpha-synuclein  level [54]. 
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The importance to maintain such balance for the 
living system was marked by A. Szent-Györgyi [55] 
in the mid-XXth century; he considered the balance 
between electron donors and acceptors to be one of 
the basic life parameters.  
Associated redox system representing 
combination of redox cycles of carbon, nitrogen, 
oxygen and sulphur, has been formed during the 
evolution process [56]. Redox potential of the 
normally functioning cells is maintained at the 
constant level and changes only under specific 
actions [1, 34, 57-59]. In spite of the fact that 
oxidation-reduction reactions are the basic reactions 
of the bioenergetic processes and regulate cellular 
activity as a whole [27], there is no clear 
understanding of their role in the intra- and 
extracellular pathogenesis, signaling processes, 
homeostasis regulation. However, redox homeostasis 
acquires conceptual significance in some pathological 
body processes [60]. 
Redox potential reduction shift forms the basis 
of triggering hypoxic necrobiosis and damaging 
specific oxygen-sensitive cells; redox potential 
oxidation shift forms the basis of developing free-
radical necrobiosis and apoptosis of trophic cells [1]. 
Oxidative and nitrosative stress removes SH-SS 
balance towards oxidated thiols that causes neurons 
necrosis and death [61]. 
Insignificant redox-potential shifts through a 
biological cycle give an opportunity to rhythmically 
regulate phases of functional activity of the living 
systems with resting phases; and its significant shifts 
lead to activation of cellular death processes. Thus, 
for example, correlation of reductive and oxidated 
glutathione levels plays role of a special “switch” 
from proliferation phase to differentiation phase and 
further to apoptosis [62]. 
Redox potential shift has an effect on realization 
of metabolic processes, work of the signaling 
transduction system, gene expression, activity of 
transcription factors [63-66], change of activity and 
biological full value of both intracellular 
compartments and a cell as a whole [67]. When 
changing redox potential status cellular strategy is 
mostly defined by the status of signal transmitting 
systems [68]. Redox potential has been demonstrated 
to be an indicator of cellular functional activity and 
effectiveness of anti-oxidated protection [69].  
Organic substances (vitamins, aminoacids) and 
compounds of inorganic origin – macro- and 
microelements - take part in redox potential 
regulation alongside with oxygen; even insignificant 
change of concentration of inorganic substances has 
an effect on the functioning of the whole body [1, 70] 
The data obtained on the leading role of redox 
potential in maintaining the biological system 
regulation give new opportunities for 
pharmacotherapy of pathological conditions 
including hypoxic one. Currently the amount of 
theoretical, experimental and clinical data is 
sufficient to create a theory of developing highly 
effective medications of new generation – redox 
regulators – based on the study of functional 
biological multivaluedness of redox-active agents. 
The enormous list of modern preparations for 
chemotherapy is represented by chemical compounds 
foreign for the biological system, having xenobiotic 
load on a body and, consequently, causing side 
effects. Therapeutical effect of any xenobiotic is 
restricted by the blockage of adaptational body 
reactions to a damage and replacement of the proper 
protective resource into the artificial one until its 
atrophy. Besides, introduction of foreign medications 
can result in resistance that increases danger of 
overdose and individual hypersensitivity. Severe 
drawbacks of modern medications are reported to be 
a narrow range of pharmacological activity and 
absence of selectivity towards a biotarget; that is why 
a positive result in vivo for a foreign compound is 
accidental; this fact is proved by rare successful cases 
of numerous chemicals screening. 
Synthesis of effective and safe medications – 
natural participants of enzymatic reactions and 
metabolism compatible with biological structures and 
systems, - is possible by applying electrophilic 
replacement, redox vitamin modification and 
complex formation.  The example of redox vitamin 
modification appears to be an effective 
polyfunctional preparation – mexidol – vitamin B6 
modification (redox oxypyridine active centre) with 
succinate [71]. 
Analysis of numerous investigations of this 
medication allows concluding that vitamin B6 easily 
entering a cell through its own natural canals 
transfers a succinate; this makes mexidol an 
irreplaceable pathogenetic preparation in complex 
therapy of post-hypoxic conditions [72, 73].  Vitamin 
B6 as an active redox agent participates in the 
regulation of oxidation-reduction processes in cytosol 
and membrane, and a succinate metabolite – succinic 
acid – reactivates cell respiration. Due to such 
synchronic tandem cells living activity remains 
unchanged and a chance to restore cellular functional 
activity under oxygen deficiency increases. 
Impact of succinate on the energy exchange has 
been studied more in details for all substrates of the 
Krebs cycle [74]. Predominant use of succinate is 
natural cell protection against hypoxia. At that, 
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replenishment of the substrate fund may occur as a 
result of the Krebs cycle reactions, both – linear and 
reverse. Such a peculiarity of oxidative 
phosphorylation provides an opportunity to reverse 
reaction at the di-carbon stage of the Krebs cycle 
with transition of fumarate into succinate and 
increasing amount of the latter. Mechanism of 
inversive fumarate transformations during the Krebs 
cycle explains the efficient use of fumarate-
containing preparation – sodium fumarate, mafusol, 
polyoxifumarin, konfumin, as well as the complex 
fumarate + Hydroxyethylstarch, which is successfully 
passing through the last stage of pre-clinical trials 
[75, 76]. Preparations of this group have come to stay 
in the program of fumarate-containing solutions for 
infusions applied in Accident and Emergency 
Departments of healthcare facilities in the Russian 
Federation and CIS-states when delivering medical 
care to the injured in military conflicts, natural and 
technological disasters [77]. 
Currently there has been shown an opportunity 
of redox potential pharmaco-correction of heart 
failure caused by ischemic heart disease with 
adenosine containing reduced NAD form [78]; there 
have been revealed pre-conditions for Histochrom 
application in complex therapy of venous retinal 
occlusions associated with changes of the redox 
system [79]. 
Redox regulators take the exceptional position 
among biomolecules, because only redox-active 
substances are able to transfer electrons 
intermolecularly. Since charge redistribution is 
considered to be a basis of a biochemical reaction, 
then only redox-active elements and molecules 
specific for the given enzyme play the functional 
role. This explains synchronization of biological 
processes occurring at all levels of the systemic 
organization influenced by associated redox-factors. 
At that, the significance of the unique organization of 
a protein molecule or its active polypeptide part is 
evident.  
An attempt to change redox potential of the 
body liquid media with ionized liquid having either 
positive or negative potential has been made in the 
Voronezh N.N.Burdenko State Medical University 
[80, 83]. Some research studies performed prove safe 
application of fluids with various redox potential, 
establish therapeutic range of the redox potential 
parameter in millivolts [81, 82].    
Variety of biological systems, numerosity of 
active particles and secondary messengers, 
complexity of the inflammatory reaction mechanism 
and variety of factors influencing it do not allow 
creating a precise picture of mechanisms, which 
realize protective potential of safe medications. 
However, universe character of their participation in 
these mechanisms as a redox potential agent supports 
not only reasonability but also the necessity of 
creating such agents.  
Redox agents perform an antioxidant function as 
constituents of the physiological antioxidant system, 
however, the fact of even greater importance is that 
they provide functional enzymes activity as co-
enzymes, co-substrates and co-factors, i.e. reveal 
prooxidant activity. More than that, redox agent 
activity is defined by the redox environment, mainly, 
protein having signaling transduction.  
General principle of endogenic redox regulators 
impact is aimed at three biological flows: metabolic, 
energetic and informational; their synchronic 
interaction at all levels of organization of the living 
system is achieved due to redox factors incorporation 
into enzymatic processes. Simultaneously they act as 
sensors responding to changes of one of the most 
important indicators of the biological system – redox 
potential. A received signal is directly or indirectly 
transformed into activity shift of a specific enzyme.  
Currently redox-sensitive elements of the 
intracellular signal-transmitting systems (p 38 MAP 
kinase, JNK, transcription factors and proteins of 
Bcl-2 family) are shown to be molecular targets for 
therapeutic correction of the apoptotic program 
violation under oxidative stress [68].  
In the extreme (pathological) situation 
associated with hypoxia anti-oxidants are able to 
reveal their own protective function acting as an 
electron buffer. Redox-active agents, on the contrary, 
produce induction and mobilization of all protective 
resources at any level of the biological system 
demonstrating not only anti-oxidant, but pro-oxidant 
activity as well. The problem to be studied is how to 
trigger these processes and further regulate them.  
If a danger of stress-reaction is insignificant and 
the amount of operative protective resource is 
sufficient enough to eliminate its consequences, then 
participation of endogenic redox regulators may be 
considered as manifestation of their preventive 
potential.  
Different situation occurs if the amount of 
protective resource is insufficient and it is necessary 
to mobilize specific protective proteins, information 
on which is kept in the genetic material. It is the 
medication based on modified signaling molecules of 
proteins that should participate in the mechanisms of 
induction and mobilization of protective resource. 
Such varieties of redox-active signaling molecules 
performing the role of the protective function trigger 
may claim to be highly effective medications.
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Development of organic complexes of biometals 
seems to be the most universal. In this case organic 
bioligand being a natural redox-active agent of an 
enzyme allows an element to be the most effectively 
included in the metabolic mechanism. Such complex 
compounds of transitional biometals may reproduce 
chemical behaviour of metalo-enzymes in a cell. The 
role of these complexes is restricted by the 
participation of electrons and redox-reactions typical 
for this enzyme in the processes of transport. Low-
molecular compounds with metals, for example, zink 
sulfate or gluconate, cannot be referred to the 
category of redox regulators, since absence of a 
relevant ligand in their composition deprives these 
compounds of substrate specificity. Taking into 
account high level of biological activity of essential 
bioelements their reliable and fast delivery by 
transport proteins with easier release appears to be a 
warrant of high effect. 
Conclusion. Thus, any violation of homeostasis 
results in pathological conditions causing violation of 
energy production, storage and utilization. Redox-
potential is considered to be the basic indicator of 
metabolic cell status integrating uncountable number 
of oxidation-reduction reactions. The data available 
on the leading role of redox-potential changes in 
providing the biological systems regulation give new 
opportunities for pharmacotherapy of pathological 
conditions including hypoxic ones. Development of 
medications – redox system regulators – aimed at the 
induction of proper protective body resource appears 
to be strategic concern of creating new generation 
pathogenic therapy agents. 
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